Scripps Research Logo

News Release

Scripps Florida Scientists Predict Cell Changes that Affect Breast Cancer Growth, Opening Door to More Effective Therapies

JUPITER, FL – April 28, 2016 – Designing effective new drugs, especially drugs to fight cancer, demands that you know as much as you can about the molecular workings of cancer growth. Without that, it’s like planning to fight a war against an enemy you’ve never seen.

Using a broad spectrum of analytical tools, scientists from the Florida campus of The Scripps Research Institute (TSRI) have shown how sometimes small, often practically imperceptible, structural changes in a key breast cancer receptor are directly linked to regulating molecules and can produce predictable effects in curbing or accelerating cancer growth.

This predictive statistical approach, published recently in the journal Molecular Systems Biology, moves science one step closer to the development of more effective structure-based drug design to treat the disease.

“Our long-term goal,” said team leader Kendall Nettles, an associate professor at TSRI, “is to be able to predict proliferative or anti-proliferative activity of receptor molecule complexes by identifying structural changes that lead to specific outcomes. In many cases, we can identify structural features that could help guide more effective drug development.”

To identify the root of estrogen receptor (ERα) cell signaling that drives breast cancer cell proliferation, Nettles and his colleagues synthesized more than 240 estrogen receptor binding molecules (“ligands”) that led the cancer to proliferate, using structural analysis to determine the basis for receptor activity.

Many current drugs target signaling proteins like the estrogen receptor. For example, the drug tamoxifen (Nolvadex®, AstraZeneca) blocks the estrogen receptor’s proliferative effects of naturally occurring estrogen in breast cancer cells, but can increase the risk of uterine cancer.

Research Associate Sathish Srinivasan, a co-first author of the study with Research Associate Jerome Nwachukwu, pointed out the new research suggests that certain structural changes might be made to the binding pocket to eliminate this negative side effect. “Drugs like tamoxifen can have different effects in different tissues because of structural changes often not discernable using traditional methods,” Srinivasan said. “Our approach reveals some mechanisms associated with tissue specificity and several predictive structural features."

To further test these signaling models, the team solved the atomic structure of some 76 different estrogen receptor-ligand complexes to better understand these responses.

“We can predict some of these effects by measuring the distance between two specific carbon atoms of the estrogen receptor,” said Nwachukwu. 

Nettles concluded, “This is the first time we have been able to use these atomic structures to identify how very small changes from the ligands give different outcomes, leading us towards the goal of predicting which ligands are going to make the most effective treatments for breast cancer.” 

In addition to Nettles, Nwachukwu and Srinivasan, authors of the study, “Predictive Features of Ligand-Specific Signaling through the Estrogen Receptor,” include Hai-Bing Zhou, Yangfan Zheng, Song Wang, Chune Dong and Zongquan Liao of Wuhan University (China); Jason Nowak and Nicholas J. Wright of TSRI; René Houtman of PamGene International (The Netherlands); Kathryn E. Carlson, John A. Katzenellenbogen and Jian Min of the University of Illinois; Jatinder S. Josan of Virginia Tech; and Olivier Elemento of Weill Cornell Medical College.

The work was supported by the National Institutes of Health (PHS 5R37DK015556, 3 5R33CA132022 and 5R01DK077085), Frenchman’s Creek Women for Cancer Research, BallenIsles Men’s Golf Association, National Science Foundation (1359369), National Science Foundation of China (20872116, 81172935, 81373255), Key Project of Ministry of Education (313040) and Open Research Fund Program of the State Key Laboratory of Virology of China (2011002).

About The Scripps Research Institute

The Scripps Research Institute (TSRI) is one of the world's largest independent, not-for-profit organizations focusing on research in the biomedical sciences. TSRI is internationally recognized for its contributions to science and health, including its role in laying the foundation for new treatments for cancer, rheumatoid arthritis, hemophilia, and other diseases. An institution that evolved from the Scripps Metabolic Clinic founded by philanthropist Ellen Browning Scripps in 1924, the institute now employs more than 2,500 people on its campuses in La Jolla, CA, and Jupiter, FL, where its renowned scientists—including two Nobel laureates and 20 members of the National Academy of Science, Engineering or Medicine—work toward their next discoveries. The institute's graduate program, which awards PhD degrees in biology and chemistry, ranks among the top ten of its kind in the nation. For more information, see www.scripps.edu.

# # #

For information:
Office of Communications
Tel: 858-784-2666
Fax: 858-784-8118
press@scripps.edu


Kendall Nettles is an associate professor at the Florida campus of The Scripps Research Institute. (High-res image)


FOR MORE INFORMATION